Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abvc Biopharma (ABVC) EBITDA (2016 - 2025)

Abvc Biopharma (ABVC) has disclosed EBITDA for 13 consecutive years, with -$2.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA fell 268.95% year-over-year to -$2.8 million, compared with a TTM value of -$7.9 million through Dec 2025, down 58.17%, and an annual FY2025 reading of -$7.9 million, down 58.17% over the prior year.
  • EBITDA was -$2.8 million for Q4 2025 at Abvc Biopharma, down from -$2.0 million in the prior quarter.
  • Across five years, EBITDA topped out at -$370346.0 in Q3 2024 and bottomed at -$8.4 million in Q4 2021.
  • Average EBITDA over 5 years is -$2.5 million, with a median of -$2.0 million recorded in 2022.
  • The sharpest move saw EBITDA crashed 459.23% in 2022, then soared 91.34% in 2023.
  • Year by year, EBITDA stood at -$8.4 million in 2021, then skyrocketed by 46.74% to -$4.5 million in 2022, then skyrocketed by 91.34% to -$386064.0 in 2023, then crashed by 94.22% to -$749822.0 in 2024, then plummeted by 268.95% to -$2.8 million in 2025.
  • Business Quant data shows EBITDA for ABVC at -$2.8 million in Q4 2025, -$2.0 million in Q3 2025, and -$2.2 million in Q2 2025.